ArticleSurgical neurology international2025
Role of inflammatory markers in differentiation and prognostication of gliomas - A prospective cohort study.
Article in Surgical neurology international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The tumor microenvironment is an indispensable component of the tumorigenesis of gliomas. Retrospective studies reveal that certain inflammatory markers could represent the aggressive variants due to the systemic inflammation associated with them. The primary objective is to study the association between procalcitonin (PCT), C-reactive protein (CRP), and hematological inflammatory markers in gliomas. The secondary objective is to prognosticate gliomas using the Karnofsky performance score (KPS) at 6 months based on these markers. Methods: This prospective cohort study comprises 100 patients diagnosed with glioma radiologically. Multivariate logistic regression analysis was performed to assess the association of the biomarkers with KPS, and the Odds ratio (OR) was calculated. Results: 92.8% of all glioma patients had PCT <0.05 ng/dL, and 85.4% had low CRP of <0.3 mg/L. High-grade gliomas (HGGs) had a low median basophil count compared to low-grade gliomas ( Conclusion: We found no significant association between PCT, CRP, and inflammatory biomarkers with grades of gliomas. However, there was a significant difference in the distribution of basophil count between the two groups. Further studies are required to validate their role in gliomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.